The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual Report (2022)”, providing insights into the adverse drug reaction (ADR) landscape in China. The National Adverse Drug Reaction Monitoring Network received 2,023,000 ADR\/Event Report Forms and 642,000 new and serious ADR\/Event reports during the year. The report indicates no significant change in the reporting of ADRs in 2022 compared to the previous year.<\/p>\n\n\n\n
Chemical Drugs and Oncology Drugs Dominate ADR Reports<\/strong>
Chemical drugs accounted for 82.3% of ADR\/Event reports, with traditional Chinese medicines (TCM) at 12.8%, and biological products at 2.6%. Within the chemical drugs category, oncology drugs topped the list of ADR\/Event reports. The top five categories with the highest number of cases were anti-infective drugs, tumor drugs, cardiovascular system drugs, analgesics, electrolyte\/acid-base balance, and nutritional drugs. The proportion of reported anti-infective drugs continued to decline. Among serious reports involving chemicals, cancer drugs were the most commonly reported, accounting for 35.1%, followed by anti-infective drugs at 27.8%.<\/p>\n\n\n\n